Using a Mathematical Model to Analyze the Role of Probiotics and Inflammation in Necrotizing Enterocolitis by Arciero, Julia C. et al.
Using a Mathematical Model to Analyze the Role of
Probiotics and Inflammation in Necrotizing Enterocolitis
Julia C. Arciero
1*, G. Bard Ermentrout
1, Jeffrey S. Upperman
2, Yoram Vodovotz
3, Jonathan E. Rubin
1
1Department of Mathematics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 2Department of Surgery, University of Southern California, Los
Angeles, California, United States of America, 3Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Abstract
Background: Necrotizing enterocolitis (NEC) is a severe disease of the gastrointestinal tract of pre-term babies and is
thought to be related to the physiological immaturity of the intestine and altered levels of normal flora in the gut.
Understanding the factors that contribute to the pathology of NEC may lead to the development of treatment strategies
aimed at re-establishing the integrity of the epithelial wall and preventing the propagation of inflammation in NEC. Several
studies have shown a reduced incidence and severity of NEC in neonates treated with probiotics (beneficial bacteria
species).
Methodology/Principal Findings: The objective of this study is to use a mathematical model to predict the conditions
under which probiotics may be successful in promoting the health of infants suffering from NEC. An ordinary differential
equation model is developed that tracks the populations of pathogenic and probiotic bacteria in the intestinal lumen and in
the blood/tissue region. The permeability of the intestinal epithelial layer is treated as a variable, and the role of the
inflammatory response is included. The model predicts that in the presence of probiotics health is restored in many cases
that would have been otherwise pathogenic. The timing of probiotic administration is also shown to determine whether or
not health is restored. Finally, the model predicts that probiotics may be harmful to the NEC patient under very specific
conditions, perhaps explaining the detrimental effects of probiotics observed in some clinical studies.
Conclusions/Significance: The reduced, experimentally motivated mathematical model that we have developed suggests
how a certain general set of characteristics of probiotics can lead to beneficial or detrimental outcomes for infants suffering
from NEC, depending on the influences of probiotics on defined features of the inflammatory response.
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Introduction
Necrotizing enterocolitis (NEC) is a severe disease of the
gastrointestinal (GI) tract that is characterized by increased
permeability of the intestine and is primarily observed in pre-term
babies. Although the causes of this disease are not fully known, most
studies conclude that prematurity is the greatest risk factor. NEC
affects 7{10% of low birth weight (v1500 g) premature infants
and is observed typically within 7 to 14 days of birth [1]. Symptoms
of NEC mainly involve gastrointestinal dysfunction, such as
abdominal distension and feeding intolerance. Current forms of
treatment may be invasive, including surgical interventions, and are
often insufficient due to the fragility of the patients and rapid
progression of the disease. Mortality from NEC is nearly 30{50%
for infants with surgical intervention [2]. Moreover, infants who
recover from severe forms of the disease may experience
complications and other bowel disorders later in life [3–8]. The
severity of this disease, which stems from a complex inflammatory
response and immaturity of organ architecture and physiology,
coupled to a lack of effective therapy, suggests that systems
approaches such as computational modeling may be necessary to
gain a fuller insight into both mechanism and therapy.
Possible factors contributing to NEC
Although its pathophysiology is not entirely understood, NEC is
thought to be related to the physiological immaturity of the GI
tract and altered levels of normal flora in the intestines. A mature
intestine contains many defense mechanisms that act as barriers to
harmful bacteria. Many of these defense mechanisms, such as
peristalsis and tight junctions between intestinal epithelial cells
[1,3,4], are abnormal or decreased in an immature intestine, and
thus bacteria normally confined to the intestinal lumen are able to
reach systemic organs and tissues. Bacterial translocation triggers
the activation of the inflammatory response, which leads to further
epithelial damage [3,9]. The inflammatory response is often
exaggerated in premature infants due to a lack of differentiation
between harmful and beneficial bacteria [1,3].
An abnormal pattern of bacterial colonization in pre-term infants
may also contribute to the pathogenesis of NEC. Colonization by
normal (ostensibly beneficial) flora such as Bifidobacterium and
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function of the newborn intestine [1,4,10,11]. Premature infants in
the neonatal intensive care unit are more likely than other infants to
be colonized by pathogenic bacteriadueto the use ofantibioticsand
feeding instrumentation. In addition, formula-fed infants are
colonized with a complex flora containing a much lower amount
of Bifidobacteria than the amount found in breast-fed infants, and
indeed, pre-term infants fed formula have significantly higher rates
of NEC than those fed breast milk [12].
Recently, Toll-like receptor-4 (TLR-4) has been shown to be
significantly increased in mice and humans with NEC compared
with healthy infants [13]. Since TLR-4 expression can cause
increased apoptosis of intestinal epithelial cells and reduced
intestinal healing, TLR-4 signaling may also play a significant
role in the development of NEC. Together, immaturity of the GI
tract and the inflammatory response, abnormal intestinal bacterial
colonization, and altered TLR-4 signaling at least partly account
for the increased risk for pre-term babies to develop NEC.
Possible treatment for NEC
Given this growing understanding and identification of the
factors that contribute to NEC, it seems important to develop
treatment strategies aimed at bolstering the integrity of the
epithelial wall, preventing excessive inflammation, and limiting the
presence of pathogenic bacteria. One proposed treatment method
is the administration of probiotics, which are defined as non-
pathogenic species of bacteria that promote the health of the host
[14]. Probiotics used to treat NEC consist mainly of Bifidobacterium
and Lactobacillus. Probiotics compete with pathogenic bacteria for
host binding sites and nutrients while also stimulating host defense
mechanisms and enhancing intestinal maturation. Probiotic
bacteria can protect against systemic bacterial invasion by
decreasing the permeability of the gastrointestinal wall [10,11].
Several studies have shown a reduced incidence and severity of
NEC in neonates treated with probiotics [12,14–20]. Hoyos et al.
[18] noted an almost threefold reduction in the incidence of NEC
after the administration of probiotics that included Lactobacillus
acidophilus and Bifidobacterium infantis. Infants treated with a
probiotic mixture in two separate studies [19,20] showed a
reduced incidence of NEC and decreased disease severity. Despite
these trends, the appropriate timing and dosing of probiotic
administration have not been determined. In addition, questions
regarding the safety and efficacy of delivering probiotic bacteria to
pre-term infants have not been fully answered, since not all studies
have shown beneficial effects of probiotics. In a study by Dani
et al. [21], infants treated with Lactobacillus were shown to have an
increased incidence of sepsis, and the observed decrease in NEC
incidence was not statistically significant. Similarly, Land et al.
[22] observed cases of Lactobacillus sepsis in infants treated with
probiotics. However, lactobacillemia can occur naturally and thus
may or may not have been related to probiotic treatment.
Current model
Experimental studies have shown a potential clinical benefit of
probiotics in NEC patients but have not identified the mechanisms
underlying the efficacy of probiotic treatment. It is hypothesized that
probiotics improve the barrier function of the intestine by increasing
transepithelial resistance, protecting against cell death, inducing
specific mucus genes, and stimulating the production of nonfunc-
tional receptor decoys in the intestinal lining [1,4]. Probiotics have
also been shown to decrease cytokine activation so as to prevent an
exaggerated inflammatory response [1] and to inhibit TLR-4
expression so as to reduce the development of NEC [13].
We hypothesized that the protective potential of these
mechanisms can be analyzed using a mathematical model.
Building upon insights established by theoretical models of the
acute inflammatory response [9,23–26], the current study aims to
analyze the impact of pathologic bacteria in the context of NEC,
as motivated by Hunter et al. [27], and to predict the conditions
under which probiotics may be successful in promoting the health
and survival of infants at risk for NEC. Pathogenic and probiotic
bacteria populations initially present in the intestinal lumen are
simulated using an ordinary differential equation model. The
degree of intestinal wall permeability is a variable in the system
that corresponds indirectly to the role that Damage-associated
Molecular Pattern (DAMP) molecules play in propagating the
positive feedback between inflammation and damage [28,29].
Based on this permeability, the conditions leading to bacterial
translocation into the systemic circulation can be predicted. In the
model, the inflammatory response targets pathogens while
simultaneously causing increased damage to the intestinal wall.
System behavior in the presence and absence of probiotics is
compared, and the relative therapeutic contributions of various
hypothesized effects of probiotics are analyzed. Since predicted
health and disease states are shown to be sensitive to the initial
degree of infection and virulence of the pathogen, the model can
be used to define a set of conditions under which clinical studies
should be conducted to identify the situations in which probiotic
treatment is beneficial and to optimize probiotic administration.
Methods
A system of ordinary differential equations is used to track both
pathogenic and probiotic bacteria in two compartments: an
intestinal lumen compartment and a combined blood/tissue
compartment(see Figure1).Therate of‘‘leakiness,’’orpermeability
to bacteria (i.e., efflux of bacteria), of the intestinal epithelial layer is
treated as a variable. Initially, both pathogenic and probiotic
bacteria are present only in the lumen. Transport of these
populations into the blood/tissue compartment is assumed to occur
across weakened tight junctions in the epithelium due to the
immaturity of the gut [3], through damaged regions of the
Figure 1. Schematic diagram of compartmental model for
necrotizing enterocolitis. Two compartments are considered: the
intestinal lumen and a combined blood/tissue compartment.
BL~pathogenic bacteria in the lumen. BPB,L~probiotic bacteria in
the lumen. e~permeability of epithelial wall. B~pathogenic bacteria in
the blood/tissue. BPB~probiotic bacteria in the blood/tissue.
M~immune cells in the blood/tissue.
doi:10.1371/journal.pone.0010066.g001
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(e.g., TLR-4) [4]. Immune cells are present in the blood/tissue
region and become activated once bacteria enter the blood/tissue
region. The success of the inflammatory response in eliminating
pathogens comes at the cost of additional damage that the
inflammatory response causes to the intestinal wall. Bacterial
permeability is assumed to increase in proportion to the
inflammatory response.
The majority of the parameter values for this model are taken
directly from two previous models of the inflammatory response
[9,23]. The remaining unknown parameters are approximated
according to experimental observations and biological assump-
tions. Table 1 gives a list of the different populations that are
tracked by this model, and Table 2 gives the values, descriptions,
and sources of the model parameters.
Intestinal lumen compartment
In the intestinal lumen, pathogenic bacteria (BL) and probiotic
bacteria (BPB,L) are assumed to compete with each other for
resources and nutrients. This process is modeled using a
competitive logistic interaction in equations (1) and (2).
dBL
dt
~r1BL 1{
BLza1BPB,L ðÞ
K1

{eBL ð1Þ
dBPB,L
dt
~r2BPB,L 1{
(BPB,Lza2BL)
K2

{ekBPB,L ð2Þ
de
dt
~
e0{e
t
z
fM
1zcBPB,L
emax{e ðÞ ð 3Þ
The pathogenic and probiotic bacteria populations have growth
rates r1 and r2 and carrying capacities K1 and K2, respectively. In
this model, the carrying capacity of pathogenic bacteria is assumed
to be higher than that of probiotic bacteria, K1wK2. Probiotic
bacteria are assumed to have a strong effect on the growth rate of
pathogenic bacteria, and thus the competition parameters a1 and
a2 in equations (1) and (2) satisfy a1wa2. The second term in each
of equations (1) and (2) describes the transfer of bacteria
populations from the lumen into the blood/tissue compartment,
which depends on the intestinal wall permeability. The rate of
bacterial efflux through the intestinal wall is given by e and is
tracked in equation (3). The model is used to study scenarios of
health and disease in premature infants. Bacterial permeability is
initially given by a low but nonzero value, e0~0:1 h{1.
Physiologically, this baseline permeability would correspond to a
gut lining that is not fully developed or to an initial breakdown in
the intestinal barrier due to the activation of TLR-4. Even in
mature infants, baseline intestinal permeability would not be zero
since the model should accomodate the possibility that a
sufficiently large bacterial insult will lead to bacterial translocation
and blood infection. Also, animal studies have suggested that the
intestinal lining is permeable to fluorescein isothiocyanate-labeled
dextran even under control conditions [30]. Despite the nonzero
initial condition for bacterial permeability, if the levels of
pathogenic and probiotic bacteria in the lumen remain sufficiently
low, bacteria are assumed not to translocate into the blood and
tissues. The parameter f in equation (3) indicates the extent to
which epithelial damage is caused by the inflammatory response.
Since probiotics have been shown to enhance the viability of the
intestinal barrier [1,10,11], parameter c is varied in the system to
assess the potential beneficial effect of probiotics on intestinal wall
permeability. Parameter emax is defined as the maximum possible
rate of bacterial permeability and has value 0:21 h{1. In a study
by Han et al. [30], ileal permeability in mice increased slightly
more than two-fold in the presence of lipopolysaccharides (LPS)
with time; this provides an experimental basis for the ratio of emax
to e0 used in our model.
Blood/tissue compartment
Equations (4)–(6) represent the evolution of pathogenic bacteria
(B) and probiotic bacteria (BPB) in a lumped blood/tissue
compartment.
dB
dt
~ e BLzkBPB,L ðÞ {T ½  z
BL
BLzkBPB,L

{k5MB ð4Þ
dBPB
dt
~ e BLzkBPB,L ðÞ {T ½  z
kBPB,L
BLzkBPB,L

{k6MBPB ð5Þ
dM
dt
~
n1 c1Bzc2BPB ðÞ
n2zc1Bzc2BPB
{mM ð6Þ
We assume that the rate at which bacteria enter this combined
compartment depends on the permeability of the epithelial layer as
well as on the number of bacteria present, relative to a threshold T.
Thethreshold corresponds biologicallyto the resistance providedby
the intestinal wall to the translocation of bacteria and is motivated
by an experiment [30] in which the number of bacteria that
permeated the intestinal wall was shown to increase as a step-
function with time: after 6 hours, no bacteria had entered the
systemic circulation, but after 12 hours, the number of bacteria that
permeated the intestinal wall increased sharply and remained at this
maximum value for an additional 6 hours. This experimental
observation is captured using the function x ½  z :~maxfx,0g. The
threshold term e(BLzkBPB,L){T ½  z in each of equations (4) and
(5) is multiplied by a ratio to ensure that the only source of
pathogenic (probiotic) bacteria entering the blood/tissue compart-
ment is the pathogenic (probiotic) bacteria in the lumen.
Biologically, it is unclear if pathogenic bacteria and probiotic
bacteria are equally effective at breaching the epithelial barrier.
Since probiotics are typically considered as beneficial to the host, it is
hypothesized that more probiotic bacteria than pathogenic bacteria
must be present in the lumen in order to exceed the threshold and
enter the blood/tissue. In support of this hypothesis, Hooper and
Macpherson [31] suggest that, under most circumstances, the
Table 1. Variables for NEC model.
Variable Description
BL Pathogenic bacteria in the intestinal lumen
BPB,L Probiotic bacteria in the intestinal lumen
e Permeability of intestinal wall to bacteria
B Pathogenic bacteria in the blood/tissue
BPB Probiotic bacteria in the blood/tissue
M Activated inflammatory cells
doi:10.1371/journal.pone.0010066.t001
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triggering a systemic immune response. To explore this concept in
the current model, a parameter k that varies between 0 and 1 is used
to scale the contribution of probiotic bacteria to exceeding threshold
andtriggeringbacterialtranslocationfromthelumenintotheblood/
tissue compartment. If k~1, then pathogenic and probiotic bacteria
are equally able to enter the blood/tissue, whereas if k~0, then only
pathogenicbacteriawillbreachtheepitheliallayer.Althoughasingle
species of bacteria has not been associated with all cases of NEC, the
Gram-negative Enterobacteriaceae are the most common species
isolated from infants with NEC [4]. Normal flora such as
Bifidobacterium and Lactobacillus are Gram-positive. This difference
in bacterial type may partially explain the difference in the body’s
reactions to harmful and beneficial bacteria. Moreover, as described
by Hooper and Macpherson [31], a particular bacterial species can
range significantly between benign and pathogenic, promoting
health in some cases but causing harm in others.
Pathogenic and probiotic bacteria are assumed to be destroyed
by activated inflammatory cells (M) in the blood/tissue at rates k5
and k6, respectively. In equation (6), inflammatory cells are
assumed to be activated by both pathogenic bacteria and probiotic
bacteria. We hypothesize that pathogenic bacteria exert a stronger
influence than probiotic bacteria on inflammatory cell activation
[32], represented by c2vc1. Finally, inflammatory cells are
assumed to decay/die with rate m.
Results
To investigate various features of probiotic treatment for NEC, we
first consider equations(1)–(6) inthe absenceof probiotics for varying
levelsofinitialpathogenicinsult,BL(0). Next, the effects of probiotics
on the growth of pathogenic bacteria in the lumen, on the
permeability of the epithelial wall, and on the activation of the
inflammatory response are analyzed. The mechanisms underlying
the beneficial effects of probiotic treatment are investigated, and the
components ofanideal probiotictreatment strategyaresummarized.
Inspection of system (1)–(6) shows that model steady states can
take two forms, one with baseline bacterial permeability (e~e0)
and no bacteria present in the blood/tissue compartment, and
another with an elevated bacterial permeability and a nonzero
presence of bacteria in the blood/tissue compartment. We refer to
the former as the health state and the latter as the disease state.
Model predictions in the absence of probiotics
In the absence of probiotics in the system, BPB,L~BPB~0. The
thin curves in Figure 2 illustrate that a health state is maintained if a
low level of pathogenic bacteria, BL(0)~10|106 cells/g, is initially
introduced with a pathogenic bacteria growth rate (virulence) of
r1~0:35 h{1 and a threshold of T~1:5|106 cells/g/h. Since the
product of the bacterial permeability rate and the level of
pathogenic bacteria in the lumen (eBL) does not exceed T,t h e
levels of bacteria and inflammatory cells in the blood/tissue are zero
(B~0 and M~0) for all time, and the bacterial permeability
remains at its baseline value. If the initial level of bacteria in the
lumen is increased, for example to BL(0)~15:5|106 cells/g, then
eBL is initially above threshold and bacteria enter the blood/tissue;
however, the infection is successfully cleared in the blood/tissue
region by the inflammatory cells and a health steady state is restored
(Figure 2, thick, blue curve). If a sufficiently large number of
pathogenic bacteria is initially present in the system (e.g.,
BL(0)~20|106 cells/g), then the threshold value is exceeded. A
disease state is predicted, since pathogenic bacteria are never
entirely cleared from the blood/tissue compartment and inflam-
mation persists (Figure 2, dashed curve). Thus, we observe
bistability of steady states in the system for r1~0:35 h{1.
In Figure 3A, the steady state values of eBL are plotted as a
function of the pathogenic growth rate, r1, for two different initial
conditions: BL(0)~10|106 cells/g (.) and BL(0)~20|106
Table 2. Parameter values for NEC model.
Parameter Value Unit Description Source
r1 0:1{11 =h growth rate of pathogenic bacteria in lumen [9]
r2 0:1{0:51 =h growth rate of probiotic bacteria in lumen
a1 0:6 competitive effect of BPB,L on BL in lumen
a2 0:4 competitive effect of BL on BPB,L in lumen
K1 20 106cells=g carrying capacity of BL [9]
K2 10 106cells=g carrying capacity of BPB,L
e0 0:11 =h baseline rate of bacterial translocation [30]
emax 0:21 1=h maximum rate of bacterial translocation [30]
t 24 h time scale for epithelium repair
f 0:51 =½Munits  effect of inflammatory response on permeability
c 0:35 10{6g=cells effect of probiotics on permeability
k 0{1 contribution of probiotics to threshold crossing
m 0:05 1=h decay rate of inflammatory cells [23]
k5 25 1=h=½Munits  rate of destruction of pathogen by M
k6 25 1=h=½Munits  rate of destruction of probiotic bacteria by M
n1 0.08 [M units]/h source of inflammatory cells [9]
n2 0.12 1=h decay of inflammatory cells [9]
c1 0.1 10{6g=cells=h rate of inflammatory cell activation due to pathogen [9]
c2 0.01 10{6g=cells=h rate of inflammatory cell activation due to probiotics [9]
doi:10.1371/journal.pone.0010066.t002
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are the theoretical lower and upper bounds on eBL in steady state,
and the thin horizontal line is the value of the threshold parameter
T. For consistency, a health steady state with BL~  B BL can only
exist if e0  B BLvT, while a disease steady state with BL~  B BL and
e~  e ewe0 can only exist if   e e  B BLwT. For both initial conditions,
simulations yield convergence to a health state if r1v0:312 h{1
and convergence to a disease state for r1w0:4 h{1. Interestingly,
both health and disease steady states are stable for
0:312 h
{1ƒr1ƒ0:4h
{1. For values of r1 in this range, a disease
state is predicted if BL(0)~20|106 cells/g whereas a health state
is predicted if BL(0)~10|106 cells/g.
The bistable region can be identified precisely using the e{BL
phase plane shown in Figure 3B. The slope of the
dBL
dt
nullcline
depends on r1 and determines the intersection point of the
dBL
dt
(blue) and
de
dt
(red) nullclines. We define r1~r1,a to be the infimum
of the set of r1 values at which the nullclines intersect three times
and r1~r1,b to be the supremum of this set. For values of r1
outside of ½r1,a,r1,b , the nullclines intersect only once: for r1vr1,a a
health state is always predicted, and for r1wr1,b a disease state is
always predicted. For r1,aƒr1ƒr1,b, selection of health or disease
depends on the initial bacterial insult, BL(0). The nullclines
corresponding to r1,a and r1,b are labeled in Figure 3B, and sample
trajectories (.) using the initial conditions from Figure 3A are also
shown. The square on the
de
dt
nullcline represents the point at
which bacteria exceed threshold and translocate into the blood/
tissue compartment (i.e., BL~
T
e0
~15|106 cells/g). At this point,
the equation defining the
de
dt
nullcline changes from e~e0 (below
threshold) to e~
e0(1zcBBP,L)zfMtemax
1zcBPB,LzfMt
(above threshold).
In summary, Figure 3 illustrates the mechanisms underlying the
steady state outcomes in the model in the absence of probiotics
and the dependence of the model prediction of health or disease
on the initial pathogen level and pathogen growth rate r1.I n
particular, the bistability evident in Figure 3 arises in a parameter
regime in which the inherent growth rate of the pathogenic
bacteria population does not allow those bacteria to exceed the
threshold level required to enter the blood/tissue compartment.
Yet, if a sufficient number of pathogenic bacteria is introduced
from an outside source, a sustained blood/tissue infection will
result. We shall see that this bistability persists when probiotics are
Figure 2. System dynamics in the absence of probiotics. Health
or disease states are predicted as the initial level of pathogenic bacteria
is varied: BL(0)~10|106 cells/g (thin curve, health), BL(0)~15:5|106
cells/g (thick blue curve, health), and BL(0)~20|106 cells/g (dashed
curve, disease). The growth rate of pathogenic bacteria is r1~0:35 h{1
and the threshold is T~1:5|106 cells/g/h. (A) Bacteria in lumen. (B)
Permeability. (C) Bacteria in blood/tissue. (D) Inflammatory cells.
doi:10.1371/journal.pone.0010066.g002
Figure 3. Steady state predictions in the absence of probiotics. (A) Steady state values of pathogenic bacteria and permeability as the growth
rate of pathogenic bacteria (r1) is varied. Steady state solutions of eBL are given by (.) for BL(0)~10|106 cells/g and (0) for BL(0)~20|106 cells/g.
In the bistable region, steady state solutions are exactly e0BL or close to emaxBL (curves labeled) depending on the initial level of pathogenic bacteria.
Thin horizontal line: threshold, T~1:5|106 cells/g/h. (B) e{BL phase plane corresponding to system dynamics in panel A. A region of bistability is
predicted when the
dBL
dt
(blue) and
de
dt
(red) nullclines intersect three times. This occurs for values of r1 within ½r1,a,r1,b  (corresponding nullclines
included). Trajectories for BL(0)~10|106 cells/g when r1~r1,a~0:312 h{1 and BL(0)~20|106 cells/g when r1~r1,b~0:4 h{1 are also shown. The
closed square gives the value of bacteria at which threshold is exceeded and bacteria are able to translocate into the blood/tissue.
doi:10.1371/journal.pone.0010066.g003
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affect steady state outcomes.
Model predictions in the presence of probiotics
The addition of probiotics as a treatment method has two
important effects on the system: probiotics compete with
pathogenic bacteria in the lumen and they reduce the permeability
of the intestinal wall. These effects are captured in the model by
parameters a1 and a2 in equations (1) and (2) and by parameter c
in equation (3). Parameter k also encodes an important aspect of
the hypothesized effect of probiotics in the system. Bacteria enters
the blood/tissue compartment if e(BLzkBPB,L) exceeds the
threshold; k provides a measure of the contribution of probiotics
to crossing the threshold. In Figure 4, the steady state values of BL,
BPB,L, and e are calculated, and e(BLzkBPB,L) is plotted as a
function of k in the presence (dashed, solid, and dash-dotted lines)
and absence (blue line) of probiotics for three different probiotic
growth rates. In the three cases shown, the pathogen growth rate is
r1~0:3h
{1, and the probiotic growth rate is r2~0:1, 0:28, and
0:5 h{1, respectively. The initial number of probiotic bacteria in
the lumen is BPB,L(0)~1|106 cells/g. Curves are shown for a
small initial bacterial insult, BL(0)~10|106 cells/g, for which the
system converges to a health state for all parameter sets
considered. This choice highlights the effects of k and r2 and the
competition between probiotic and pathogenic bacteria in the
lumen in the absence of bacterial translocation through the
epithelium. In all cases, the curves generated with probiotics
present intersect the line corresponding to the absence of
probiotics at k~0:6~a1 (the logistic growth competition
parameter). Direct computation of BL and BPB,L steady states
from equations (1) and (2), with e~e0, shows that if kva1, then
probiotics are a beneficial treatment method since the steady state
value of the sum e(BLzkBPB,L):bss,k in the presence of
probiotics is less than the steady state value of eBL:bss,0 in the
absence of probiotics. This outcome implies that
T{bss,kwT{bss,0. For kwa1, probiotics are harmful since
bss,kwbss,0. This outcome implies that threshold could be
exceeded in the presence of probiotics even though this threshold
is not exceeded in the absence of probiotics. For small r2 (dashed),
the presence of probiotics has nearly no effect for k above some
level, including kwa1, since pathogenic bacteria are predicted to
outcompete probiotics in that parameter range. For sufficiently
high r2 (dash-dotted), probiotics result in decreased luminal
bacteria levels for kva1 and elevated levels for kwa1.
Time dynamics for the system in the presence of probiotics are
illustrated in Figure 5. The system is simulated in the bistable
region, with r1~0:35 h{1, r2~0:28 h{1, T~1:5|106 cells/
mL/h, BL(0)~15|106 cells/g, and BPB,L(0)~1|106 cells/g.
Model predictions for multiple values of k are shown:
k~0,0:3,0:5,0:7,1.F o rkw0, e(BLzkBPB,L) is above threshold
at t~0 due to the initial levels of bacteria in the lumen, and thus
there is an initial efflux of bacteria into the blood/tissue. For
k~0:3 (green curve) and k~0:5 (blue curve), the inflammatory
response is ultimately successful at eliminating bacteria in the
blood/tissue, and the competitive effects of probiotics cause the
overall number of bacteria in the lumen to be decreased from its
initial value so that e(BLzkBPB,L) falls below threshold and
bacterial permeability returns to the baseline value. Thus, the
beneficial role of probiotic bacteria is evident as k is decreased
since probiotics are increased in the lumen, which causes
pathogenic bacteria to be decreased in the lumen due to
competition with probiotics and translocation into (and eventual
Figure 4. Steady state values of e( (BLzkBPB,L) ) in the absence and presence of probiotics for varied k values. Thick, blue line: steady
state value of eBL (no probiotics, labeled). Thin, dashed line: threshold value, T. Steady state values of e(BLzkBPB,L) are shown for a small initial
bacterial insult (BL(0)~10|106 cells/g) and the following parameter combinations: r1~0:3 h{1 and r2~0:1 h{1 (dashed curve), r1~0:3 h{1 and
r2~0:28 h{1 (solid curve), and r1~0:3 h{1 and r2~0:5 h{1 (dashed-dotted curve). Note, parameters are labeled as (r1,r2) on the figure.
doi:10.1371/journal.pone.0010066.g004
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(black curve) and k~1 (dashed curve), however, e(BLzkBPB,L)
remains above threshold (panels H, I) and the observed decrease
in luminal bacteria is due to the sustained efflux of bacteria
into the blood/tissue. Interestingly, the steady state levels
of both pathogenic and probiotic bacteria in the lumen are
non-monotonic functions of k, and increased permeability
can maintain a disease state despite smaller luminal bacteria
levels for large k. These results illustrate that model predic
tions of health and disease depend on the transient dynamics of
bacteria in the lumen as well as the immune response and its
consequences.
The maximal and minimal steady state curves for the product of
luminal bacteria and intestinal permeability in the absence of
probiotics (Figure 6A: blue curves, as in Figure 3) are shifted to the
right with respect to r1 in the presence of probiotics, as illustrated
in Figure 6A for k~0:3 (black curves). As a result, the regions of
disease and bistability occur at higher values of r1, indicating the
beneficial effect of probiotics on the system. This effect is also
observed in Figure 6B, since the intersection point of the
dBL
dt
and
de
dt
nullclines corresponding to a disease steady state is lost as
parameter k is decreased from 0:5 (blue) to 0:3 (red) (note that the
initial condition BL(0)~20|106 cells/g lies in the basin of
attraction of the disease state for k~0:5).
Although the regionof bistability shiftsto largerr1 valueswith the
introduction of probiotics, this rightward shift is less pronounced for
larger k. Moreover, the level of BL(0) separating the basins of
attraction of the health and disease states depends on k in addition
to r1. These trends can be seen in Figure 6C, which shows the
boundary between initial conditions yielding health and those
leading to disease as a function of r1 in the absence and presence of
probiotics for various k values and r2~0:28 h{1. For any fixed k,
for low values of r1, the inflammatory response successfully
eliminates bacteria from the blood and tissue compartment so that
a health state is always predicted. For high values of r1, a level of
bacteria persists in the blood/tissue, and a disease state is predicted.
Forintermediatevaluesofr1,bistablityoccurs,suchthatbothhealth
anddiseaseoutcomesarepossible,dependingonBL(0).Forbistable
values of r1, some BL(0) values that were in the health region
without probiotics actually lie in the disease region with probiotics
present, for sufficiently large k (e.g. k~0:5 and k~0:6 in
Figure 6C). As k is decreased, probiotics contribute less to threshold
crossing and the health region expands.
Five labeled points are included in Figure 6C to highlight the
predicted model behavior for different bacterial initial conditions
and virulence. At point A, which would have led to a disease state
without probiotics, health is restored in the presence of probiotics
with kƒ0:5. For a more virulent pathogen with the same BL(0),
represented by point B, a disease state is always predicted by the
model, irrespective of probiotic treatment (assuming k§0:3). In
general, in the absence of probiotics, an increase in the initial
number of bacteria (from point D to A) or growth rate of pathogen
(from point D to C) corresponds to a change from predicted health
to predicted disease states. In the presence of probiotics with
sufficiently small k, a health state is maintained despite traversing
from points D to A or points D to C, demonstrating the benefit of
probiotic treatment. However, point E lies in the region where the
Figure 5. System dynamics in the presence of probiotics. Health or disease states are predicted as parameter k is varied: k~0 (red), 0:3
(green), 0:5 (blue), 0:7 (black), and 1 (dashed). The system is simulated in the bistable region, with initial pathogenic bacteria insult BL(0)~15|106
cells/g, pathogenic bacteria growth rate r1~0:35 h{1, and probiotic bacteria growth rate r2~0:28 h{1. (A) Bacteria in lumen, BL. (B) Probiotic
bacteria in lumen, BPB,L. (C) Permeability, e. (D) Bacteria in blood/tissue, B. (E) Probiotic bacteria in blood/tissue, BPB. (F) Immune cells, M. (G) Total
bacteria in lumen, BLzkBPB,L. (H) Product of luminal bacteria and permeability, e(BLzkBPB,L). (I) Difference between product in (H) and threshold,
e(BLzkBPB,L){T.
doi:10.1371/journal.pone.0010066.g005
Role of Probiotics in NEC
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10066model predicts that probiotic treatment can actually be harmful,
lowering the level of BL(0) needed to induce disease, for a certain
range of k. For this parameter set, probiotics contribute to threshold
crossing in the model, enhancing the immune response and further
increasing permeability in a way that is not resolved by subsequent
decreases in luminal bacterial levels. The existence of such a region
may help explain clinical studies in which probiotics did not reduce
the incidence of NEC and in fact led to bacterial sepsis [21,22].
Figure 6D provides a summary of predicted health and disease
regions in the (k,r1) plane. The overlap in health and disease
regions corresponds to the bistable region in which the initial
degree of infection, BL(0), dictates the outcome. If r1 is small
enough, then probiotics can outcompete pathogenic bacteria.
However, for very virulent strains of pathogen (high r1 and k), the
pathogenic bacteria outcompete probiotics.
Based on our model formulation, as k is decreased, probiotics
becomeprogressively more beneficial tothesystem.Inaddition, asc
is increased, epithelial permeability to bacterial translocation is
reduced, which also promotes health. These effects are consistent
with the natural expectation that probiotic strains characterized by
a small k value (corresponding to a low tendency toward epithelial
translocation) and a large c value (representing strong anti-
inflammatory effects on epithelial permeability) are likely to yield
the optimal treatment outcome. Just as seen with the introduction of
probioticsinFigure6A,a decreaseink shiftsthesteadystate bounds
on luminal bacteria levels to the right with respect to r1. Curves for
k~0:5 (blue curves, circles) and k~0:3 (black curves, squares) are
shown inFigure 7A.Disease and bistability arepredicted to occur at
higher values of r1 for decreased k values, yielding a larger region of
predicted health. Changes in c affect the location of the e-nullcline.
In Figure 7B, a shift in the
de
dt
nullcline is evident for increased c
values. The red curve indicates the
de
dt
~0 nullcline for c~0:35;i fc
is increased to c~2:0, the
de
dt
nullcline (black) lies entirely at e~e0
and only healthy outcomes can result for all BL(0) in the range
shown. The tradeoff of parameters c and k is investigated in
Figure 7C for an initial state that would yield disease in the absence
of probiotics (r1~0:4 h{1 and BL(0)~20|106 cells/g). The
regions of predicted health and disease are identified for three
different values of probiotic growth rate, r2. Regions above the
given curve correspond to combinations of parameters c and k that
yield predictions of health, and regions below each curve
Figure 6.Systembehavior in the presence of probiotics. (A) Steadystate values of bacteria and permeabilityinthe presence of probiotics as the growth
rate of pathogenic bacteria (r1) is varied. e0(BLzkBPB,L) and emax(BLzkBPB,L) curves in the presence (black line, k~0:3) and absence (blue line) of
probiotics are included. Steady state values of e(BLzkBPB,L),w i t hk~0:3,a r eg i v e nb y( .)f o rBL(0)~10|106 cells/g and (0)f o rBL(0)~20|106 cells/g, as
in Figure 3A. (B) e{BL phase plane (magnified) corresponding to system dynamics in panel A with BL(0)~20|106 cells/g. The
de
dt
~0 and
dBL
dt
~0 nullclines
are shown for k~0:5 (blue) and k~0:3 (red). Trajectories for k~0:5 and k~0:3 (., labeled) indicate predicted disease and health states, respectively. (C)
Predictions of health and disease for various initial numbers of pathogenic bacteria (BL(0)) and pathogenic bacteria growth rates. Thick, black curve: separates
regions of health and disease in the absence of probiotics. Solid curves separate regions of health and disease in the presence of probiotics with
c~0:35|10{6 g/cell and k~0:6 (red), 0:5 (blue), and 0:3 (green). System behavior is investigated at five points, A–E. (D) Predicted regions of health and
disease are separated by a thick solid line and a dashed line, respectively, as parameters k and r1 are varied. Bistability of stable health and disease states occurs
for values of k and r1 in the overlap of the health and disease regions. A summary of system dynamics is also included and separated by thin, solid curves.
doi:10.1371/journal.pone.0010066.g006
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predicted since more probiotics are present in the system. A health
state independent of the value of c is predicted for kƒ0:1, given the
parameter values considered here. We observe greater sensitivity to
c when c is small than when it is large, suggesting that effects of
probiotics on epithelial permeability are saturating, while sensitivity
to k dominates once c is large enough.
The effect of r2 on the curves separating health and disease in
the (r1,BL(0)) plane with k~0:5 is shown in Figure 7D. Due to
the threshold term in equation (5), increasing the growth rate of
probiotics is expected to have a similar effect as increasing the
effectiveness of probiotics (i.e., decreasing parameter k), and
indeed Figure 7D is very similar to Figure 6C. In general, as r2 is
increased from 0:1 to 0:5 h{1, the region of predicted health
increases. However, as is evident from the intersection of the
curves in the bistable region, at least for small r2, there are some
values of BL(0) for which health would have resulted in the
absence of probiotics yet disease is predicted with probiotics.
The interplay between probiotics and the activation of the
inflammatory response is investigated in Figure 8. While an
increased inflammatory response helps the system to defeat an
invading pathogen, the inflammation that accompanies the
inflammatory response causes damage to the intestinal barrier,
thereby increasing the permeability e of the layer. Parameter c2
gives a measure of immune activation due to probiotics. System
behavior for various c2 values is illustrated in Figure 8. The system
is assumed to be initially in the bistable region, 0:33ƒr1ƒ
0:37 h{1, with BL(0)~15|106 cells/g. In panel A, for each fixed
r1, a disease outcome is predicted once parameter c2 exceeds a
certain level, which decreases as r1 increases. For r1w0:37 h{1,
disease is predicted for all values of c2, and when r1v0:33 h{1,
health is predicted unless c2 is increased outside of the biologically
relevant regime. In panel B, the system is also simulated in the
bistable region with r1~0:35 h{1. We chose BL(0)~15|106
cells/g, which yields health for all c2 for k~0:3.A sk increases, the
outcome depends on c2. Health is lost at a fixed value of c2 for
k~0:5, because additional immune activation leads to too much
intestinal permeability to overcome. If k is sufficiently large, such
as k~0:7, then disease results for all c2, with the steady-state value
of e increasing as a function of c2.
Figure 7. Effect of parameters k and c on system behavior. (A) System behavior for two k values (parameter relating the probiotic
contribution to threshold crossing) as the growth rate of pathogenic bacteria (r1) is varied. Curves as in Figures 3A and 5A. Steady state solutions of
e(BLzkBPB,L) are shown for BL(0)~10|106 cells/g (closed symbols) and BL(0)~20|106 cells/g (open symbols) with k~0:5 (circles) and k~0:3
(squares). (B) e{BL phase plane (magnified) as parameter c is varied in the system. The
dBL
dt
~0 (blue) and
de
dt
~0 nullclines for c~0:35|10{6 g/cell
(red) and c~2:0|10{6 (black) are shown. Trajectories (.) for both c values are included. (C) Regions of health and disease predicted by the model as
c and k are varied. The system is initially in a disease state defined by BL(0)~20|106 cells/g and r1~0:4 h{1. Combinations of c and k values above
each curve represents regions in which health is restored. Values of parameter k is varied in the range in which probiotics are predicted to be
beneficial: 0ƒkƒ0:6. Curves for different probiotic bacteria growth rates (r2) are included: r2 =0.1, 0.28, and 0.5 h{1. (D) Effect of initial number of
pathogenic bacteria (BL(0)) and probiotic bacteria growth rate (r2) on predictions of health and disease is shown as r1 is varied. Thick black curve:
separates regions of health and disease in the absence of probiotics. The following curves separate regions of health and disease in the presence of
probiotics with c~0:35|10{6 g/cell and k~0:5: r2~0:1 h{1 (red), r2~0:28 h{1 (blue), and r2~0:5 (green).
doi:10.1371/journal.pone.0010066.g007
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Our model predicts that the time, duration, and dose level of
probiotic administration can determine its effectiveness at
restoring health. A probiotic dose is simulated in the model by
adding a constant sw0 to the right hand side of equation (2) for a
fixed time period. In Figure 9, the minimal duration of probiotic
dose required to yield a health state is investigated as the initial
time of probiotic administration and the probiotic dose levels are
varied. These effects are studied for two different initial levels of
pathogenic bacteria. Points above the curves correspond to dosing
parameters yielding a health state. In Figure 9A, the dashed curve
corresponds to an initial disease state given by the following
conditions and parameters: BL(0)~20|106 cells/g, r1~0:35 h{1,
k~0:5,a n dc~0:35. A probiotic dose of s~1:25|106 cells/g/h is
used in panel A. The length of time for which probiotics must be
administered at a particular dose in order to restore health (defined
here as the threshold dose duration) is predicted to increase as the
timeatwhichprobioticsareadministered isdelayed.Thisoutcomeis
expected, since administering probiotics for a shorter period of time
will be effective in a system that has not yet reached a steady state
value for disease. Once a steady state is reached, the necessary
threshold dose duration does not change. A negative relationship
Figure 8. Interplay of probiotics and inflammatory response. (A) Model predictions of health and disease as parameters c2 (the activation of
the inflammatory response due to the presence of probiotic bacteria in the blood/tissue) and r1 (the growth rate of pathogenic bacteria) are varied.
System is simulated in the bistable region, with initial pathogenic bacteria insult BL(0)~15|106 cells/g, probiotic contribution to threshold crossing
k~0:5, and probiotic bacteria growth rate r2~0:28 h{1. (B) Effect of inflammatory response activation by probiotic bacteria (c2) on the permeability
of the intestinal wall (e). Baseline permeability is e0~0:1 h{1. Parameter k is varied: k~0:3, 0:5, and 0:7 (labeled).
doi:10.1371/journal.pone.0010066.g008
Figure 9. Effect of peak, duration, and timing of administration of probiotics. Curves denote minimal duration for which a dose of
probiotics (s~1:25|106 cells/g/h) must be adminstered to result in health (defined as threshold dose duration). Two different initial bacteria levels
are considered: BL(0)~15|106 cells/g (solid) and BL(0)~20|106 cells/g (dashed). In all simulations, c~0:35|10{6 g/cells and k~0:5. (A) Change
in the threshold dose duration for probiotic administration as the time of administration is varied. (B) Change in the threshold dose duration for
probiotic administration as dose level (s) is increased.
doi:10.1371/journal.pone.0010066.g009
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predicted when BL(0)~15|106 cells/g, r1~0:35 h{1, k~0:5,
and c~0:35 (solid curve).In thiscase(Figure6C,pointE),probiotics
can have the harmful effect of lowering the level of BL(0) needed for
disease to result. Waiting before giving probiotics allows BL to
decrease on its own, such that the threshold dose duration decreases.
InFigure9B,resultsareshownfromsimulationswiththesameinitial
conditions as in panel A. The threshold dose duration required to
restore health is predicted to decrease as the probiotic dose level is
increased. However,ifthesystem isinitiallyinthe part ofthe bistable
regioninwhichthe presenceofprobioticsisharmfulto thesystem(as
in Figure 6C, point E), then the threshold dose duration required to
restore health first increases with dose level before it decreases.
Discussion
The model presented in this study represents a preliminary tool
for exploring the effects of probiotic treatment for NEC. The
model incorporates several experimentally supported mechanisms
through which probiotics can mitigate effects of pathogenic
bacteria on the immature gut. Specifically, probiotics affect the
number of pathogenic bacteria in the lumen as well as the overall
number of bacteria there, the degree of epithelial wall permeabil-
ity, the number of bacteria in the blood/tissue, and the activation
of the inflammatory response. We simulated the model equations
for different levels of initial pathogenic insult, BL(0), and different
parameter values associated with the relative strengths of these
mechanisms.
Dependence of model dynamics on parameters
associated with probiotics
Mattar et al. [33] showed that the presence of probiotics in the
intestinal lumen generally leads to a decrease in the level of
pathogen in the lumen. Our results agree with this finding,
assuming a1wa2. Figure 6D shows that probiotics can outcompete
pathogenic bacteria if the growth rate of these pathogens is small,
while a high enough pathogen growth rate can allow these bacteria
to predominate over probiotics. We find that under most
conditions, the two species coexist in the lumen. For a fixed
threshold parameter T, the translocation of bacteria is determined
by the product of two factors, namely the effective size of the
luminal bacteria population BLzkBPB,L and the epithelial
permeability e. As seen in Figure 4, as long as the parameter k
is below a1, the presence of probiotics decreases the steady state
value of this product. This decrease may allow the system to avoid
bacterial efflux into the blood/tissue and the associated inflam-
matory response, or it may allow the system to exhibit a weaker
flux of bacteria through the epithelium if a lowering of the
epithelial permeability threshold were to occur. The ability of
probiotics to decrease epithelial permeability itself, which is
analogous to our e, was verified by Kennedy et al. [10] and is
demonstrated in Figure 7, in which a health state is promoted as
parameter c (a measure of the probiotic effect on permeability) is
increased. As a result of these effects, the number of bacteria in the
blood/tissue is predicted to be decreased. However, even if
pathogenic and probiotic bacteria enter the blood/tissue com-
partment, probiotics activate inflammation to a lesser degree than
do pathogenic bacteria. This effect is observed experimentally [32]
and in our model is due to the assumption that c1wc2 in equation
(6).
The most interesting feature of our model’s dynamics is the
bistability between health and disease states that occurs over a
range of pathogenic growth rates in the transition between health-
only and disease-only regimes. The epithelial barrier is a key
component of this bistability. Specifically, this barrier prevents
activation of the inflammatory response when the number of
luminal bacteria is below a threshold [30], allowing for a stable
health state. For the same parameter values, however, a transient
elevation in the number of pathogenic bacteria that leads to
translocation across the epithelial barrier stimulates an inflamma-
tory response. This response can be advantageous, since the
inflammatory cells eliminate pathogenic bacteria, yet the activa-
tion of these inflammatory cells also enhances epithelial perme-
ability and effectively reduces the threshold. Combined, these two
processes can result in the emergence of a stable disease state
(Figure 8). The introduction of probiotics into the lumen yields a
decrease in the total size of the steady state bacterial population in
the lumen in the absence of threshold crossing (Figure 4 and 5G).
Probiotics may contribute to a transient elevation in total luminal
bacteria, however, which may produce an efflux into the blood/
tissue when this threshold crossing effect is taken into account.
Thus, the presence of probiotics may negatively impact patients by
paradoxically lowering the level of pathogenic bacteria required to
induce a disease outcome. The larger the value of parameter k, the
lower this necessary number of pathogenic bacteria becomes
(Figure 6C). Clinical studies have shown both positive and
negative outcomes when probiotics are administered to premature
infants [18–22]. Points A–E in Figure 6C have been selected to
illustrate how outcomes of different treatment strategies could
depend quite sensitively on the size of an initial pathogenic insult,
the virulence of the pathogen, and the characteristic k of the
probiotics. At points A, C, and E, both health and disease states
are possible and depend on initial conditions and parameters,
while at B and D, outcome is independent of probiotics for the
parameter range considered. At point E, probiotic administration
converts a health outcome to a disease outcome, while the opposite
can be true at A and C, depending on the nature of the probiotics
applied. This sensitivity suggests that multiple conditions should be
tested clinically in efforts to identify the potential benefit and harm
of probiotic treatment.
Modeling specific patient populations and interventions
In addition to infection type and severity, many experiments
have indicated that the effectiveness of probiotic treatment on the
incidence of NEC may also depend on feeding type, delivery type,
and health disorders of the infant (e.g., hypoxia). For example,
studies have shown that breast-fed infants acquire a more desirable
intestinal flora than formula-fed infants, since breast milk contains
many antimicrobial products and factors that promote the
colonization of helpful bacteria in the infant intestine [3,34,35].
In fact, a 10-fold increase in the incidence of NEC was found in
formula-fed infants compared with breast-fed infants [4]. The
effects of breast-feeding could be simulated using our mathemat-
ical model by decreasing the growth rate of pathogenic bacteria
(r1), decreasing the damage caused by the inflammatory response
(f), decreasing the carrying capacity of pathogenic bacteria (K1),
and decreasing the baseline epithelial permeability (e0). It is
important to note, however, that, since breastfeeding is the
biological norm for the infant digestive system, these adjustments
should be thought of as restoring the model system to a baseline
state, whereas the parameters used throughout this paper
represent a perturbation to this baseline state, associated with
the regime in which NEC is likely to occur. Clearly, different
interventions should be designed for formula-fed versus breast-fed
infants, given the differences between these two populations.
Studies have also shown that infants born vaginally tend to be
colonized earlier with beneficial species of bacteria, while infants
delivered by cesarean section have a delayed colonization by
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luminal probiotic bacteria could be assumed to be higher in infants
born vaginally to distinguish birth type. In addition, premature
infants with NEC are often treated with antibiotics and other
methods that aim to reduce their load of pathogenic bacteria.
These interventions, however, also affect their normal gut
colonization and can increase NEC severity. The effects of
antibiotics have been included in previous models of infection and
acute inflammation [25] and can be simulated in the current
model by decreasing parameters r1 and r2, the growth rates of
pathogenic and probiotic bacteria. Importantly, the killing of
bacteria with antibiotics may release factors that trigger the release
of immunostimulants, thereby contributing to the overwhelming
degree of inflammation observed in NEC. NEC has been observed
occasionally in full-term babies but is often associated with infants
suffering from cyanotic congenital heart disease, a hypoxic-
ischemic event, polycythemia, or in utero growth restriction [3,4].
These diseases are associated with a history of hypoxia, in which
the resulting decrease in blood supply may affect the integrity of
the intestinal lining. To account for a hypoxic event in the model,
the baseline level of epithelial permeability e0 could be increased.
Because our model has been developed such that key parameters
control effects of infection and of probiotic treatment, it can be
used to investigate various experimental observations through
adjustments in parameter values and initial conditions. Although
the model has been developed specifically to address the incidence
of NEC in neonates, many gastrointestinal diseases exhibit similar
mechanisms and characteristics, and thus this model may also be
adapted to investigate other gastrointestinal disorders in a variety
of age groups.
Determining the correct probiotic dosing strategy is a key
question for the realization of effective probiotic treatment for
infants suffering from NEC. Our mathematical model predicts
that probiotics will be most effective for low rates of pathogenic
growth (r1), moderate rates of probiotic growth (r2), high levels of
probiotic reduction of epithelial permeability (c), and a low ability
of probiotics to cross the epithelial barrier (k). In clinical studies of
probiotic supplements administered to pre-term neonates, the time
at which probiotics are administered varies between 0 and 7 days
of birth [3,18,20,21]. Also, the studies implement different
numbers of doses per day and include multiple probiotic species.
It is hypothesized that treatment with a mixture of probiotic strains
as opposed to a single strain may have an improved effect on
preventing NEC in premature infants [16]. In future work,
information obtained from simulating the model using different
dosing regimens (Figure 9) and different initial conditions and
parameter values (Figure 6C), customized to represent particular
probiotic treatment conditions, may be used to predict outcomes
of probiotic treatment strategies. Moreover, an optimal control
approach may be applied to the model to generate optimal dosing
time courses.
Additional considerations and conclusions
Our main motivation in designing this study was to incorporate
experimental observations of probiotics into a mathematical model
that can be used to gain insight into key interactions of pathogens,
probiotics, and the inflammatory response in the context of NEC.
In this way, we hope to improve clinical translation, as part of our
larger Translational Systems Biology framework [29,36–39]. In
particular, we have included mathematical terms in our model
that represent important effects that have been implicated in the
development of NEC and some of the mechanisms through which
probiotics are thought to act to effect its progression [1,14]. We
have utilized this model to suggest specific reasons why probiotics
might be harmful, for example by paradoxically lowering the level
of pathogenic bacteria required to induce a disease outcome, and
to highlight the features that characterize beneficial probiotics.
Our basic modeling assumption is that the inflammatory
response that takes place at the lumen/blood interface, and that
involves an interplay among intestinal flora, intestinal epithelial
cells, and inflammatory cells in the blood, serves to maintain a
dynamic equilibrium that defines the health steady state. It is likely
that an effective inflammatory response requires some small,
baseline rate of efflux of luminal bacteria into the blood/tissue.
The ensuing minor, self-limiting inflammatory response may serve
to maintain the mostly beneficial population of intestinal bacteria
while providing a sampling of intestinal contents that could lead to
an early warning of changes in the proportion of pathogenic
bacteria in the intestinal lumen. F or a developing infant, this
equilibrium may require a constant influx of factors present in
maternal breast milk. To incorporate such a baseline inflamma-
tory response, which we currently omit, the model should be
augmented to include the roles of pro- and anti-inflammatory
cytokines in the inflammatory response. One important effect of
anti-inflammatory cytokines is the reduction of damage to the
epithelium caused by the inflammatory response. In our current
model, the omission of anti-inflammatory cytokines provides a
worst-case scenario with respect to the harmful effects of the
inflammatory response. The qualitative relationships established in
this study that indicate both beneficial and harmful effects of
probiotics are still expected to hold in the presence of cytokines,
but additional insight into the interplay of the immune response
and probiotic treatment will require future modeling of cytokine
populations [40,41].
The number of experimental and clinical studies that have been
performed for NEC is limited due to the nature of the disease and
the complexity of carrying out studies and obtaining samples in
pre-term infants, and thus we used a combination of human and
animal studies to provide an experimental grounding for the
model presented. Additional experimental data would help to
determine some of the parameter values estimated in this study
and may also highlight additional factors contributing to NEC that
have not been explored by this model. Interactions between
bacteria and the inflammatory response are defined within the
context of two lumped compartments that are assumed to be well-
mixed, and thus there is no spatial component in this present
model. Immune mechanisms specific to regions such as the gut
mucosa and lamina propria [31] are not included explicitly. A
more mechanistic representation of the threshold for epithelial
permeability would also improve our model, although further
experiments are needed to provide relevant details. Interestingly, a
recent simulation study does suggest that the intensity of the
inflammatory response does depend on the phenomenon of
pathogenic growth [42], in line with our threshold-based
dependence of inflammatory activation on the extent of patho-
genic proliferation. Indeed, Hooper and Macpherson [31] suggest
that if the luminal bacterial load remains below a certain
‘‘numerical threshold,’’ then an inflammatory response is not
evoked. Overall, the hypotheses formulated using this model must
be tested with experimental work to establish under what
conditions, and through what mechanisms, probiotics can yield
beneficial effects as a treatment for NEC.
In conclusion, based on experimental and clinical studies, we
have developed a simplified mathematical model of the complex
host-pathogen interaction that occurs in the setting of NEC and
used it to analyze the impact of probiotic administration on the
ensuing dynamics. The predictions derived from this computa-
tional study may help to explain the diverse outcomes that may
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experimental and clinical studies.
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